Recommendation of the President – Briumvi (ublituximab)

On 21 March 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 33/2025 on the appraisal of Briumvi (ublituximab) within the framework of the B.29 drug program “Treatment of patients with multiple sclerosis (ICD-10: G35)”

Publication in Public Information Bulletin (BIP) >>